FTC cracks down on Q-ray bracelet
This article was originally published in The Gray Sheet
Federal Trade Commission complaint seeks a permanent injunction and redress from Q-ray ionizer bracelet company reps Que Te Park and Jung Joo Park, and associated firms QT, Inc., Q-Ray, Co. and Bio-Metal, Inc. The agency alleges that Q-ray infomercials and other promotional materials make false and misleading claims, suggesting that the ionized metal bracelet enables complete pain relief "in seconds." FTC notes that a study conducted by the Mayo Clinic last year showed no significant difference in pain relief between a placebo and the Q-ray ionized bracelet. FTC also charges the defendants with failing to honor a money-back guarantee. The bracelets list from $49.95 to $249.95...
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.